Atara Biotherapeutics(US:ATRA) TMX Newsfile·2026-03-27 13:38Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed manufacturing issues affecting the company's product approval process [2][5]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Atara between May 20, 2024, and January 9, 2026, to discuss their legal options [1]. - A federal securities class action has been filed against Atara, with a deadline of May 22, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Atara and its executives made false statements regarding the regulatory prospects of the tabelecleucel BLA, which were overstated due to manufacturing issues [5]. Group 2: Impact of FDA Response - On January 12, 2026, Atara announced that the FDA issued a Complete Response Letter for the EBVALLO™ BLA, indicating that the application could not be approved in its current form due to inadequacies in the ALLELE trial [6]. - Following the FDA's announcement, Atara's stock price fell by $7.79 per share, or 56.99%, closing at $5.88 per share [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].